We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App





Researchers Develop Accurate, High-Speed, Portable Bi-Functional Electrical Detector for COVID-19

By LabMedica International staff writers
Posted on 28 Jan 2021
Researchers have developed an unprecedented accurate, rapid, and portable electrical detector based on the use of graphene field-effect transistors (G-FETs) for the detection of RNA from COVID-19 patients.

The detection system developed by scientists at the Peking University (Beijing, China) mainly consists of two parts: a plug-and-play packaged biosensor chip and a home-developed electrical measurement machine. More...
The unique feature of this method is that the extent of hybridization between the ss-DNA probe and viral RNA can be directly converted to the current change of graphene channels without repetition of the PCR process, thus affording an ultra-low limit of detection (LOD) of 0.1 fg/mL for the detection of the RNA-dependent RNA polymerase (RdRp) gene target of SARS-CoV-2.

Furthermore, this method was validated using clinical samples collected from many patients with COVID-19 infection and healthy individuals as well, and the testing results were in full agreement with those of PCR-based optical methods. The entire process, precluding the extraction of detection targets from oropharyngeal swabs, requires approximately 10 min. Because it does not involve time-consuming PCR step nor expensive instruments, this detection system enables massive point-of-care testing of COVID-19, outside of specialized diagnostic laboratories, with the advantage of high accuracy, sensitivity and low cost.

Notably, false negative results are inevitable in the course of nucleic acid testing; thus, the use of immunodetection as an auxiliary technique is important in the diagnosis of COVID-19 patients, especially those with suspected diseases. By replacing the ss-DNA probe with a SARS-CoV-2 antigen protein, this detection system can also detect SARS-CoV-2 IgM and IgG antibodies with an ultra-low LOD of 1 fg/mL. Immunoassays of serum specimens of COVID-19 patients and healthy subjects matched excellently with those of PCR-based optical methods.

This detecting system exhibits obvious advantages of high sensitivity, rapid speed (10 min for RNA analysis and 5 min for immunoassay), and bifunction (both RNA analysis and immunoassay). These advantages enable high-throughput point-of-care testing, which may facilitate management of the current severe public health crisis. Furthermore, this detection system offers a universal methodology that is ready for immediate application in rapid detection of novel viruses in future.

Related Links:
Peking University


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.